Arena Pharmaceuticals, Inc.
If you purchased Arena Pharmaceuticals, Inc. securities and would like to join the action, please click "Join This Action" below.
ARENA MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF ARENA PHARMACEUTICALS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – ARNA
December 13, 2021.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) to Pfizer Inc. for $100.00 per share in cash is fair to Arena shareholders.
The investigation concerns whether Arena and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Arena shareholders; (2) determine whether Pfizer is underpaying for Arena; and (3) disclose all material information necessary for Arena shareholders to adequately assess and value the merger consideration. On behalf of Arena shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.